Please assess the completion status of the following clinical trial:

Trial Title: Azopt (Brinzolamide 1.0%) Plus Travatan (Travoprost 0.004%) in Treating Patients With Chronic Angle-Closure Glaucoma (CACG)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ≥ 18 years;~* CACG (Chronic Angle Closure Glaucoma) ≥ 1eye~* have been treated with PGA (prostaglandin analogues) once daily ≥ 2 weeks prior to the screening visit and IOP=19-32 mmHg (millimeters mercury) in at least one eye and ≤ 32 mmHg in both eyes~* clinical stability of VA (Visual Acuity) and optic nerve throughout the study~Exclusion Criteria:~* Abnormality restricts exam of the fundus or anderior chamber~* conjunctivitis, keratitis or uveitis~* unable to be discontinued from using all ocular hypotensive medication(s) except Travatan (Travoprost 0.004%) and/or Azopt (Brinzolamide 1.0%) for 12days-4weeks~* ocular surgery prior to the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Travoprost 0.004% + Brinzolamide 1.0% (Type: EXPERIMENTAL): Travoprost 0.004% (once daily) + Brinzolamide 1.0% (twice daily)
- Travoprost 0.004% + Tears Natural (Type: ACTIVE_COMPARATOR): Travoprost 0.004% (once daily) + Tears Naturale (twice daily)

Based on this trial design, predict the completion outcome and termination type (if applicable).